UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019894
Receipt number R000022979
Scientific Title Observation study for neuroblastoma using cell-free DNA in serum
Date of disclosure of the study information 2015/12/01
Last modified on 2022/11/28 11:14:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observation study for neuroblastoma using cell-free DNA in serum

Acronym

Observation study for neuroblastoma using cell-free DNA in serum

Scientific Title

Observation study for neuroblastoma using cell-free DNA in serum

Scientific Title:Acronym

Observation study for neuroblastoma using cell-free DNA in serum

Region

Japan


Condition

Condition

neuroblastoma

Classification by specialty

Pediatrics

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose is to observe the effectiveness of the observation infantile localized neuroblastoma without treatment prospectively

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Progression-free survival period

Key secondary outcomes

therapeutic intervention period, ratio of the tumor progression cases


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

0 days-old <=

Age-upper limit

547 days-old >=

Gender

Male and Female

Key inclusion criteria

1)day0-547days
2)Urinaly VMA and HVA level are high, the primary tumor shows positive of MIBG scintigraphy
3)L1 or L2 tumor
4) serum MYCN shows not amplification

Key exclusion criteria

1)Patients with life-threatening symptoms associated with tumor growth
2) Catecholamine secreting neuroblastoma patiets
3)physician determines patients unsuitable to participate in the study

Target sample size

45


Research contact person

Name of lead principal investigator

1st name Tomoko
Middle name
Last name Iehara

Organization

Kyoto Prefectural University of Medicine

Division name

Pediatrics

Zip code

602-8566

Address

Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, JAPAN

TEL

0752515111

Email

iehara@koto.kpu-m.ac.jp


Public contact

Name of contact person

1st name Tomoko
Middle name
Last name Iehara

Organization

Kyoto Prefectural University of Medicine

Division name

Pediatrics

Zip code

602-8566

Address

Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, JAPAN

TEL

0752515111

Homepage URL

http://www.jnbsg.jp/

Email

iehara@koto.kpu-m.ac.jp


Sponsor or person

Institute

Japan Neuroblstoma Study Group

Institute

Department

Personal name



Funding Source

Organization

AMED

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kyoto Prefectural University of Medicine

Address

Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, JAPAN

Tel

0752515111

Email

iehara@koto.kpu-m.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 12 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Date of protocol fixation

2015 Year 11 Month 15 Day

Date of IRB


Anticipated trial start date

2015 Year 12 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Observation of the final cases registered after one year


Management information

Registered date

2015 Year 11 Month 22 Day

Last modified on

2022 Year 11 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022979


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name